Edden, Y <br/><br/>
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.  [electronic resource] 

 -  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland  May 2012 
 - 555-61 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1463-1318 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1318.2011.02697.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--metabolism<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Apoptotic Protease-Activating Factor 1--metabolism<br/>Biomarkers, Tumor--metabolism<br/>Chemoradiotherapy<br/>Chi-Square Distribution<br/>Cyclin-Dependent Kinase Inhibitor p21--metabolism<br/>Cyclin-Dependent Kinase Inhibitor p27--metabolism<br/>Cyclooxygenase 2--metabolism<br/>Dose Fractionation, Radiation<br/>Female<br/>Fluorouracil--therapeutic use<br/>Humans<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Rectal Neoplasms--metabolism<br/>Statistics, Nonparametric<br/>Tumor Suppressor Protein p53--metabolism<br/>Vascular Endothelial Growth Factor A--metabolism<br/>bcl-2-Associated X Protein--metabolism